Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Active not recruiting 12Completed 6Recruiting 2Terminated 1

Sponsor Class

OTHER 15INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Metastatic Castration-Resistant Prostate Cancer 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Gonadotropin-Releasing Hormone × Clear all
NCT06065748 2026-06-04

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Hoffmann-La Roche

Phase 3 Recruiting
1,050 enrolled
Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06531499 2025-12-31

RADIODOSE

Novartis

Phase 1 Recruiting
106 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡